×
SCYNEXIS Receivables 2013-2025 | SCYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SCYNEXIS receivables from 2013 to 2025. Receivables can be defined as the total amount of collectibles for a company
View More
SCYNEXIS Receivables 2013-2025 | SCYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SCYNEXIS receivables from 2013 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$69.6B
Zoetis (ZTS)
$67.5B
Daiichi Sankyo, - (DSNKY)
$48.8B
Takeda Pharmaceutical (TAK)
$48.2B
BeOne Medicines - (ONC)
$35B
Sandoz Group AG (SDZNY)
$26.3B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.9B
United Therapeutics (UTHR)
$14.2B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.2B
IPSEN (IPSEY)
$10.6B
Eisai (ESAIY)
$9.2B
Madrigal Pharmaceuticals (MDGL)
$8.7B
Corcept Therapeutics (CORT)
$7.6B
Grifols, S.A (GRFS)
$7.3B
Ionis Pharmaceuticals (IONS)
$6.9B
Stevanato Group S.p.A (STVN)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Ono Pharmaceutical (OPHLF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Hypermarcas (HYPMY)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.4B
Ocular Therapeutix (OCUL)
$2.1B
Endo (NDOI)
$1.8B